MA37951B2 - Composite bilayer tablet formulation comprising atorvastatin, irbesartane and magnesium carbonate - Google Patents

Composite bilayer tablet formulation comprising atorvastatin, irbesartane and magnesium carbonate

Info

Publication number
MA37951B2
MA37951B2 MA37951A MA37951A MA37951B2 MA 37951 B2 MA37951 B2 MA 37951B2 MA 37951 A MA37951 A MA 37951A MA 37951 A MA37951 A MA 37951A MA 37951 B2 MA37951 B2 MA 37951B2
Authority
MA
Morocco
Prior art keywords
irbesartane
atorvastatin
magnesium carbonate
tablet formulation
bilayer tablet
Prior art date
Application number
MA37951A
Other languages
French (fr)
Other versions
MA37951A1 (en
Inventor
Yong Il Kim
Jung Hyun Cho
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37951(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA37951A1 publication Critical patent/MA37951A1/en
Publication of MA37951B2 publication Critical patent/MA37951B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation de comprimé composite bicouche comprenant (a) une première couche comportant de l'irbesartane ou son sel pharmaceutiquement acceptable, et (b) une seconde couche comportant de l'atorvastatine ou son sel pharmaceutiquement acceptable et du carbonate de magnésium (mThe present invention relates to a bilayer composite tablet formulation comprising (a) a first layer comprising irbesartane or its pharmaceutically acceptable salt, and (b) a second layer comprising atorvastatin or its pharmaceutically acceptable salt and magnesium carbonate. (m

MA37951A 2012-08-31 2013-08-30 Composite bilayer tablet formulation comprising atorvastatin, irbesartane and magnesium carbonate MA37951B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (en) 2012-08-31 2012-08-31 Bilayered tablet composite formulation of atorvastatin, irbesartan and magnesium carbonate
PCT/KR2013/007838 WO2014035188A1 (en) 2012-08-31 2013-08-30 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate

Publications (2)

Publication Number Publication Date
MA37951A1 MA37951A1 (en) 2018-06-29
MA37951B2 true MA37951B2 (en) 2019-12-31

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37951A MA37951B2 (en) 2012-08-31 2013-08-30 Composite bilayer tablet formulation comprising atorvastatin, irbesartane and magnesium carbonate

Country Status (31)

Country Link
US (1) US20150209290A1 (en)
EP (1) EP2890368A4 (en)
JP (1) JP6363079B2 (en)
KR (1) KR20140028971A (en)
CN (1) CN104602677A (en)
AR (1) AR092386A1 (en)
AU (1) AU2013309686B2 (en)
BR (1) BR112015004471A8 (en)
CA (1) CA2882735A1 (en)
CL (1) CL2015000402A1 (en)
CR (1) CR20150115A (en)
DO (1) DOP2015000040A (en)
EA (1) EA030306B1 (en)
EC (1) ECSP15010600A (en)
GT (1) GT201500043A (en)
IL (1) IL237424A0 (en)
IN (1) IN2015DN01463A (en)
MA (1) MA37951B2 (en)
MX (1) MX354800B (en)
MY (1) MY175897A (en)
NI (1) NI201500027A (en)
NZ (1) NZ706472A (en)
PE (1) PE20150935A1 (en)
PH (1) PH12015500394A1 (en)
RU (1) RU2015111546A (en)
SG (1) SG11201500584YA (en)
TW (1) TWI651101B (en)
UA (1) UA115995C2 (en)
UY (1) UY35001A (en)
WO (1) WO2014035188A1 (en)
ZA (1) ZA201502156B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (en) * 2017-01-27 2021-12-15 ニプロ株式会社 Oral solid preparation
KR102409102B1 (en) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.
PE20030324A1 (en) 2001-07-31 2003-04-03 Warner Lambert Co PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
PE20080183A1 (en) * 2006-04-06 2008-03-10 Schering Corp TRA COMBINATION THERAPIES
KR20090114320A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Pharmaceutical preparations for the treatment of cardiovascular diseases
WO2011121824A1 (en) * 2010-03-29 2011-10-06 アステラス製薬株式会社 Orally disintegrating tablet
KR101248804B1 (en) * 2010-05-14 2013-03-29 한미사이언스 주식회사 BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN

Also Published As

Publication number Publication date
MY175897A (en) 2020-07-14
ECSP15010600A (en) 2015-12-31
EA201590469A1 (en) 2015-06-30
ZA201502156B (en) 2016-07-27
IL237424A0 (en) 2015-04-30
NI201500027A (en) 2017-01-04
UA115995C2 (en) 2018-01-25
NZ706472A (en) 2018-02-23
EP2890368A4 (en) 2016-03-02
SG11201500584YA (en) 2015-02-27
DOP2015000040A (en) 2015-04-15
PE20150935A1 (en) 2015-06-20
CN104602677A (en) 2015-05-06
MX354800B (en) 2018-03-22
AU2013309686B2 (en) 2017-09-07
EP2890368A1 (en) 2015-07-08
KR20140028971A (en) 2014-03-10
CA2882735A1 (en) 2014-03-06
GT201500043A (en) 2017-08-24
MA37951A1 (en) 2018-06-29
UY35001A (en) 2014-03-31
TWI651101B (en) 2019-02-21
JP2015530384A (en) 2015-10-15
BR112015004471A2 (en) 2017-07-04
MX2015002526A (en) 2015-06-23
CR20150115A (en) 2015-04-16
WO2014035188A1 (en) 2014-03-06
CL2015000402A1 (en) 2015-06-05
BR112015004471A8 (en) 2019-08-27
AU2013309686A1 (en) 2015-02-26
PH12015500394A1 (en) 2015-04-27
IN2015DN01463A (en) 2015-07-03
EA030306B1 (en) 2018-07-31
RU2015111546A (en) 2016-10-20
TW201414507A (en) 2014-04-16
US20150209290A1 (en) 2015-07-30
AR092386A1 (en) 2015-04-22
JP6363079B2 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
BR112012024139A2 (en) double-layer pharmaceutical formulations containing opioid agonists and antagonists.
WO2012177444A3 (en) Glucagon/glp-1 receptor co-agonists
CL2014003171A1 (en) Lyophilized composition comprising at least one benzodiazepine of formula (i), at least one hygroscopic excipient selected from disacarides and dextran; method of preparation of the pharmaceutical composition.
EP2814939A4 (en) NANOPORE DETECTOR FOR THE TRANSLOCATION OF ENZYME MEDIATION PROTEIN
EP2717660A4 (en) REAR FACE PROTECTION COVER FOR ELECTRONIC TABLET TERMINAL
EP3004061B8 (en) 3,4-dihydroisoquinolin-2(1h)-yl compounds
NL1031503A1 (en) Stereoscopic display for switching between 2D / 3D images.
EA201690679A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIPIN AND VALSARTAN
DK2442790T3 (en) AURAL PHARMACEUTICAL COMPOSITIONS, CONTAINING BORATE-POLYOL COMPLEXES
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
EP3020717A4 (en) P2x4 receptor antagonist
EP2641077A4 (en) Hybrid, planar optofluidic integration
EP3061020A4 (en) Pathogenicity scoring system for human clinical genetics
FR3003747B1 (en) SYSTEM FOR ACHIEVING TWO BLOOD VESSELS.
WO2015073710A3 (en) Detection of atherosclerotic cardiovascular disease risk
EA201390335A1 (en) INTRODUCTION OF LORKASERIN TO INDIVIDUALS WITH RENAL INSUFFICIENCY
IT1397313B1 (en) CUTTING UNIT FOR MACHINE OR THERMOFORING PRESS AND THERMOFORING MACHINE EQUIPPED WITH SUCH CUTTING UNIT.
MA37951A1 (en) Bilayer composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
WO2011097527A3 (en) Immunoprotection of therapeutic moieties using enhanced fc regions
WO2011091410A8 (en) Trpv4 antagonists
MX364626B (en) Mimetic peptides.
IN2015DN01018A (en)
EA201301355A1 (en) COMPOSITION AND TABLET CONTAINING RALTEGRAVIR
EA201190282A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TAMSULUS
WO2019059868A3 (en) Pharmaceutical combinations comprising tenofovir, emtricitabine and efavirenz